Clinical Trials
95 trialsNCT07297212 2026-04-29
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT02971501 2026-04-28
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03175432 2026-04-15
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04446416 2026-04-09
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
NCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT06496971 2026-04-09
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT07481786 2026-04-06
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
Sun Yat-sen University
Phase 3 Recruiting
NCT07449481 2026-04-01
A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06888817 2026-02-25
BRAINS
The Netherlands Cancer Institute
Phase 3 Recruiting
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT02698254 2026-01-07
Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT01951482 2025-08-17
Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 3 Completed
NCT04074785 2025-08-17
SCCC-06319
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Terminated
NCT06471465 2025-08-17
BRADI
Institut Cancerologie de l'Ouest
Phase 3 Recruiting
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed
NCT01295944 2025-08-05
Carboplatin and Bevacizumab for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03698162 2025-08-05
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
University of Southern California
Phase NA Terminated
NCT05284643 2025-08-01
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
University of Miami
Phase NA Recruiting
NCT03890952 2025-07-24
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Rigshospitalet, Denmark
Phase 2 Completed
NCT04121455 2025-06-25
GLORIA
TME Pharma AG
Phase 1/2 Active not recruiting
NCT02521051 2025-05-13
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT06401824 2025-05-06
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Maastricht University Medical Center
Phase 2 Recruiting
NCT01083966 2025-04-09
Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
Northwell Health
Phase 1 Suspended
NCT01894061 2025-02-17
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01814813 2025-01-24
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT06728865 2024-12-11
Better Brain
Sun Yat-sen University
Phase 2 Recruiting
NCT05807893 2024-11-13
SUPER BRAIN
Sun Yat-sen University
Phase 2/3 Completed
NCT05271240 2024-09-19
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
Phase 3 Recruiting
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT01811498 2024-01-30
Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Northwell Health
Phase 1/2 Completed
NCT06210438 2024-01-18
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
Fudan University
Phase 2 Not yet recruiting
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04345146 2023-08-28
Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC
Sun Yat-sen University
Phase 2 Completed
NCT02490878 2023-03-23
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00312728 2023-01-06
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Genentech, Inc.
Phase 2 Completed
NCT01730950 2022-12-29
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02343549 2022-11-03
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01609790 2022-07-21
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT02010606 2021-11-22
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
Cedars-Sinai Medical Center
Phase 1 Completed
NCT00879437 2021-07-21
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Baylor College of Medicine
Phase 2 Completed
NCT02185352 2021-05-07
A-Plus
National Taiwan University Hospital
Phase 2 Unknown
NCT01290939 2021-02-15
Bevacizumab and Lomustine for Recurrent GBM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT01740258 2021-01-26
BBP
Duke University
Phase 2 Completed
NCT01125046 2021-01-22
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Phase 2 Completed
NCT00924820 2020-12-31
A Pilot Study of Bevacizumab for Neoplastic Meningitis
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00883688 2020-08-26
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00795665 2020-05-12
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Phase 2 Completed
NCT01067469 2020-03-17
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 2 Completed